BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//International Alliance of ALS/MND Associations - ECPv6.8.3//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-ORIGINAL-URL:https://www.als-mnd.org
X-WR-CALDESC:Events for International Alliance of ALS/MND Associations
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:America/Toronto
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20240310T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20241103T060000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;TZID=America/Toronto:20240318T163000
DTEND;TZID=America/Toronto:20240318T173000
DTSTAMP:20261011T085548
CREATED:20240214T112653Z
LAST-MODIFIED:20240214T112653Z
UID:16938-1710779400-1710783000@www.als-mnd.org
SUMMARY:Webinar from NEALS: The Science Behind ALS Treatments: Riluzole\, Radicava\, and Relyvrio
DESCRIPTION:Moderated by Dr. Senda Ajroud-Driss\, this webinar for both clinicians and people living with ALS will review the 3 drugs that are currently FDA-approved in the United States for the general ALS population. Panelists\, Dr. Lauren Elman\, Dr. John Novak\, and Dr. Xiaowei (Bill) Su will present information on Riluzole\, Radicava\, and Relyvrio\, including drug mechanism\, findings from clinical trials\, and potential benefits\, risks\, and costs.
URL:https://www.als-mnd.org/event/webinar-from-neals-the-science-behind-als-treatments-riluzole-radicava-and-relyvrio/
CATEGORIES:Webinar
END:VEVENT
END:VCALENDAR